Evoke Pharma (EVOK) Stock Skyrockets on Buyout News – What’s Behind the Surge?
Evoke Pharma shares jumped about 135% to $10.77 on Nov. 4, 2025, after announcing a buyout by QOL Medical for $11 per share in cash. The $17 million deal, approved by both boards, is expected to close by year-end. Evoke’s only product is Gimoti, an FDA-approved nasal spray for diabetic gastroparesis. Q2 net sales rose 47% to $3.8 million, but the company remains unprofitable.
